Last reviewed · How we verify
OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL
OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL is a marketed product developed by University Hospital, Lille, with a key composition patent expiring in 2028. The primary strength of the product lies in its established market presence, leveraging the unique properties of liquid air for medical applications. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL |
|---|---|
| Sponsor | University Hospital, Lille |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: